PT - JOURNAL ARTICLE AU - HIROYOSHI KOIDE AU - SATOSHI NODA AU - TETSUYA YOSHIDA AU - SUSUMU KAGEYAMA AU - KAZUYA TERAMURA AU - TAKESHI KATO AU - AKIHIRO KAWAUCHI AU - NORIKI FUJIMOTO AU - TOMOHIRO TERADA TI - Severe Skin Disorders Due to Sorafenib Use After Nivolumab Treatment in Renal Cell Carcinoma Patients AID - 10.21873/invivo.12591 DP - 2021 Sep 01 TA - In Vivo PG - 2969--2974 VI - 35 IP - 5 4099 - http://iv.iiarjournals.org/content/35/5/2969.short 4100 - http://iv.iiarjournals.org/content/35/5/2969.full SO - In Vivo2021 Sep 01; 35 AB - Background: We report two cases in which severe skin disorders developed during sorafenib treatment in patients with renal cell carcinoma (RCC) who had previously received nivolumab. Case Report: Case 1: A 50-year-old man with RCC received nivolumab as the fifth-line therapy followed by sorafenib as the sixth-line therapy. On day 15 of sorafenib administration, the patient was hospitalized with systemic erythema multiforme, acne-like skin rash, and hand-foot syndrome. Case 2: A 40-year-old man with RCC received nivolumab as the second-line therapy followed by sorafenib as the fifth-line treatment. On day 12 of sorafenib administration, the patient was hospitalized with an acne-like skin rash and hand-foot syndrome. The skin disorders in the two cases improved within 2-3 weeks after sorafenib discontinuation and the start of treatment with topical and oral steroids. Conclusion: When using sorafenib in patients previously treated with nivolumab, close attention should be paid to the onset of serious skin disorders.